Market Overview The CD47 antibody market is experiencing growth as this immune checkpoint target enables cancer immunotherapy through blockade of the "don't eat me" signal. The global market is projected to exceed USD 4.8 billion through 2030, driven by cancer immunotherapy advancement, combination therapy development, and clinical trial expansion. CD47 antibodies enable immunotherapy through...

According to the latest report published by Data Bridge Market Research, the Photopheresis Products Market  CAGR Value The global photopheresis products market size was valued at USD 364.24 Million in 2025 and is expected to reach USD 541.84 Million by 2033, at a CAGR of 5.09% during the forecast period The Photopheresis Products Market business research report is fragmented in...

The landscape of cancer treatment has been profoundly reshaped by the emergence of immunotherapy, a paradigm-shifting approach that harnesses the power of the body's own immune system to fight cancer. At the forefront of this revolution is pembrolizumab immunotherapy, marketed under the brand name Keytruda, and the broader class of PD-1 checkpoint inhibitors. These innovative...

The human immune system has the remarkable ability to distinguish self from non-self and to eliminate abnormal cells, including cancer. However, tumors evolve sophisticated mechanisms to evade immune detection and destruction. Immune Checkpoint Inhibitors are monoclonal antibodies that block these evasion mechanisms, "releasing the brakes" on the immune system and enabling it to...

According to the latest report published by Data Bridge Market Research, the Hodgkin Lymphoma Drug Market  CAGR Value The global Hodgkin Lymphoma Drug market size was valued at USD 3.50 billion in 2025 and is expected to reach USD 10.52 billion by 2033, at a CAGR of 14.75% during the forecast period This Hodgkin Lymphoma Drug Market research report has been formed with a...